Clinical Trial Update: Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel with or without pazopanib in persistent or recurrent ovarian, fallopian tube, or peritoneal cavity cancer completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16